Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Genes Brain Behav. 2014 Apr 30;13(5):451–458. doi: 10.1111/gbb.12137

Figure 1.

Figure 1

Visuospatial discrimination in Fmr1 KO mice is not significantly impacted by partial reduction of mGluR5 signaling. a) Schematic showing timing of treatment strategies relative to food restriction and two phases of training on a five-choice visuospatial discrimination task. b) Phase 1 acquisition is normal in Fmr1/Grm5 cross. c) There is a trend towards delayed acquisition of phase 2 as a function of Fmr1 genotype (p=.06, n=32-45). There is not a statistically significant interaction between Fmr1 and Grm5 genotypes (WT/Grm5+/+: 8.4 +/− 0.5 days to acquisition, KO/Grm5+/+: 10.6 +/− 0.7 days, KO/Grm5+/−: 8.9 +/− 0.7 days). d) In cohorts treated chronically with lovachow or similarly formulated vehicle chow, Fmr1 KO mice show impaired phase 1 acquisition (WT/vehicle: 8.3 +/− 0.4 days, KO/vehicle: 10.4 +/− 0.5 days, ***p<.001), which is not observed following lovastatin treatment (KO/lova: 9.3 +/− 0.3 days, *p<.05). e) Lovachow/vehicle cohorts show no effect of genotype or drug treatment on phase 2 acquisition.